"Time and again, Genentech is proven to be the industry leader. This is a place where creative minds have a good chance to transform medicine."
I came to Genentech as a postdoc in October 1995 to work on neural development and neural degenerative diseases. I enjoyed the dynamic and stimulating scientific environment so much that I decided to stay as a scientist. Beginning in November 1999, I started a small research lab focusing on vascular biology. Today, I am leading a multi-group program working on discovering potential treatments for a variety of diseases with vascular pathologies including exudative age related macular degeneration, diabetic retinopathy, hereditary vascular disorders, and cancer.
One of the most attractive and exciting features of being a scientist at Genentech is to mentor postdocs. Postdocs bring critical thinking, new ideas, and the youthful enthusiasm to our research programs. Mentoring postdocs energizes my mind and fuels my scientific curiosity. I truly enjoy helping them build their careers, and my group finds the postdocs an important part of our working “family”.
Science Immunology 27 Mar 2020:Vol. 5, Issue 45, eaay2245
Developmental Cell (April 2016)18;37(2):114-25. doi: 10.1016/j.devcel.2016.03.015.
We are studying how vascular alteration contributes to human diseases. For example, increased vascular permeability is an important pathologic driver in the neovascular age-related macular degeneration and diabetic macular edema. Manipulating the molecular machineries that control vascular permeability may lead to the discovery of treatments for these diseases.
We are also exploring ways to modulate the vascular barrier function in order to increase or decrease leukocyte trafficking and drug distribution in disease tissues. Increasing lymphocyte trafficking into tumors, or decreasing leukocyte trafficking into inflamed tissues may be beneficial in managing these diseases.